Comparing two types of palliative care for patients with acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research evaluates whether primary palliative care can serve as an effective alternative to specialty palliative care for patients with acute myeloid leukemia (AML). The study focuses on hospitalized patients who are experiencing significant physical and emotional distress due to their diagnosis and treatment. It aims to improve quality of life, symptoms, mood, coping, and end-of-life outcomes by comparing the two approaches to palliative care. The involvement of caregivers is also considered, as they play a crucial role in the patient's experience during this challenging time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient Inclusion Criteria

  * Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
  * Patients with new diagnosis ≥ 60 years of age
  * An antecedent hematologic disorder
  * Therapy related-disease
  * Relapsed or primary refractory AML
  * Within five business days of initiating therapy with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or b) hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial.
* Caregiver Inclusion Criteria

  * Adult (≥18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.

Exclusion Criteria:

\- Patient Exclusion Criteria

* Patients with a diagnosis of acute promyelocytic leukemia (APML)
* Patients with AML receiving supportive care alone
* Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures
* Patients seen by a palliative care clinician (MD, DO, APP) during two previous hospitalizations in the six months prior to enrollment
* Patients expected to be discharged within 2 days

Where it's running

• University of Alabama - Birmingham
  Birmingham, Alabama, United States Recruiting
• Stanford University
  Stanford, California, United States Recruiting
• University of Colorado Denver I Anschutz Medical Campus
  Denver, Colorado, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• Emory University
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Areej El-Jawahri, MD — Massachusetts General Hospital
• Study coordinator: Areej El-Jawahri, MD
• Email: ael-jawahri@partners.org
• Phone: 617-724-4000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Digital application for improving quality of life in acute leukemia patients

  This study is testing a digital app designed to help newly diagnosed acute myeloid leukemia patients improve their quality of life and cope better during their chemotherapy treatment.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06472128

• Adapt NK cells for high-risk AML bridging to stem cell transplant

  This study tests an allogeneic NK cell infusion with a brief IL-2 boost in adults with relapsed or refractory AML to see if treatment can help prepare for a future stem cell transplant.

  Recruiting Phase 1/2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07591649

• Donor γδ T cell infusion to prevent relapse after stem cell transplant in high‑risk AML

  This will test whether a donor γδ T cell infusion given soon after an allogeneic stem cell transplant can help prevent relapse in adults (18–65) with high‑risk acute myeloid leukemia.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07237230

• Venetoclax-enhanced BUCY versus standard BUCY conditioning for high‑risk AML and MDS before allogeneic stem cell transplant

  This will test whether adding venetoclax to BUCY conditioning before allogeneic stem cell transplant helps patients aged 12–60 with high‑risk AML or MDS stay in remission longer.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07183878

• Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

  This study is testing whether using special stem cells can help patients with high-risk leukemia recover their immune system faster and prevent infections after a stem cell transplant.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839456

• CD19 CAR-T therapy for adults with relapsed CD19-positive AML

  This will try CD19-directed CAR-T cell therapy in adults with relapsed or refractory AML whose leukemia cells express CD19.

  Recruiting Phase 1 University Hospital, Lille · Lille · NCT06649227

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.